Novo Nordisk Pharmatech, a unit of Novo Nordisk specialising in producing drug ingredients, has unveiled its plans to invest DKK1.5bn ($220m) to build a new plant at Ådalen 16 in Køge, Denmark.
The 8,000m² facility will address Novo Nordisk’s increasing need for raw materials to manufacture medicines for chronic diseases.
The site will include space for production, storage, office, and laboratory.
In March 2023, Novo Nordisk Pharmatech announced the acquisition of a 47,000m² site in Køge to expand its existing production facilities at Københavnsvej 216 in Køge.
The drug ingredients maker expects to create 50 new jobs with the opening of the new facility, which is expected to be completed by 2027.
Novo Nordisk Pharmatech CEO Ulla Grove Krogsgaard Thomsen said: “This is the largest investment in Novo Nordisk Pharmatech’s 75-year history. We are in a period of growth.
“In accordance with our growth strategy, we are expanding our production to ensure an even more robust and reliable delivery of our products.
“The location in Køge is ideal, as we can draw on the extensive know-how we have at our current factory – and furthermore, the infrastructure is optimal, with Køge Nord station so close to our new site.”
Novo Nordisk Pharmatech is prioritising both capacity and sustainability in this project.
Building on insights from its existing operations at Københavnsvej, the company plans to reuse key production elements and regenerate raw materials to cut its CO2 footprint by approximately 60%.
The project will also feature solar panels in the parking lot and incorporate sustainable materials in the building’s construction.
Additionally, the site will offer room for growth to align with Novo Nordisk Pharmatech’s future strategy of introducing new products to the global pharmaceutical and biopharmaceutical markets.
In early 2024, office facilities were set up at Ådalen to support project management and construction activities.
Last month, Novo Holdings, the holding company of Novo Nordisk Foundation, announced an initial investment in Danish food technology firm MATR Foods, to expand its production of sustainable meat alternatives.
